Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
Genes, Tumor Suppressor
Women with BRCA founder mutations are at increased risk for breast cancer-related events after breast conservation. However, mutation status is not an independent predictor of survival and should not influence decisions regarding adjuvant therapy. The increased contralateral breast cancer risk in women heterozygous for BRCA mutations mandates careful surveillance.